Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort.

ABSTRACT: The four dengue virus serotypes (DENV1-4) are mosquito-borne flaviviruses that infect ∼ 390 million people annually; up to 100 million infections are symptomatic, and 500,000 cases progress to severe disease. Exposure to a heterologous DENV serotype, the specific infecting DENV strains, and the interval of time between infections, as well as age, ethnicity, genetic polymorphisms, and comorbidities of the host, are all risk factors for severe dengue. In contrast, neutralizing antibodies (NAbs) are thought to provide long-lived protection against symptomatic infection and severe dengue. The objective of dengue vaccines is to provide balanced protection against all DENV serotypes simultaneously. However, the association between homotypic and heterotypic NAb titers and protection against sympt

SUBMITTER: Katzelnick LC 

PROVIDER: S-EPMC4725482 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature